2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p [q] r s t u v w x y z

Abstract Number: 50

Quality Controls Monitoring As Indicator of Stability in Bone and Cartilage Turnover Markers for Clinical Trials
Abstract Number: 2259

Quality of Life Evaluation in New Onset Juvenile Dermatomyositis Patients from the Printo Trial
Abstract Number: 2120

Quality, Content and Readability Assessment of Patient Education Websites Relating to Ehlers-Danlos Syndrome
Abstract Number: 2610

Quantiferon Testing in a Clinical Trial of Systemic Lupus Erythematosus
Abstract Number: 1027

Quantification of Leukocytes’ Secretome to Guide Diagnosis and Treatment Options in Patients with Suspected Chronic Auto-Inflammatory Syndromes
Abstract Number: 1801

Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
Abstract Number: 263

Quantitative Analysis of Vascular Calcification Using a Novel Semi-Automated Software
Abstract Number: 1698

Quantitative Analyze of Peripheral Vascular Bed in Patients with Systemic Sclerosis By Using Photoacoustic Imaging Technology: A Pilot Study
Abstract Number: 742

Quantitative CT Evalutation in Diffuse Interstitial Lung Involvement in Systemic Sclerosis: Usefulness of Lung Texture Analysis to Predict the Functional Change over Time
Abstract Number: 2141

Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage
Abstract Number: 2322

Quantitative Proteomics Comparison of Children with Inactive and Active Uveitis
Abstract Number: 2009

Quantitative Radiographic Analysis of Interstitial Lung Disease Associated with Rheumatoid Arthritis

Jump to: View All • a b c d e f g h i j k l m n o p [q] r s t u v w x y z

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.